With the help of TBWA\Chiat\Day New York, pharma giant Moderna is demystifying mRNA science for the average consumer. This ...

RFK Jr. has developed a reputation as a vaccine skeptic and pushed conspiracy theories including one linking vaccines to ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Vaccine stocks have struggled since RFK Jr.'s appointment to health secretary, with Moderna and Pfizer seeing the deepest ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $84.0, a ...

Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Next-generation COVID-19 vaccine: Moderna shared positive Phase 3 vaccine efficacy and immunogenicity data for its next-generation COVID-19 vaccine (mRNA-1283) at its R&D Day event in September 2024.